Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 21.0%

Aptorum Group Limited (NASDAQ:APMGet Rating) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 183,100 shares, a decline of 21.0% from the April 15th total of 231,800 shares. Currently, 2.1% of the shares of the company are sold short. Based on an average trading volume of 120,500 shares, the short-interest ratio is presently 1.5 days.

Shares of APM opened at $1.03 on Monday. Aptorum Group has a 12-month low of $0.86 and a 12-month high of $3.54. The stock’s 50-day moving average price is $1.34 and its 200 day moving average price is $1.65.

A number of institutional investors and hedge funds have recently modified their holdings of APM. Geode Capital Management LLC grew its stake in shares of Aptorum Group by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 312,232 shares of the company’s stock valued at $799,000 after purchasing an additional 11,009 shares during the period. Susquehanna International Group LLP grew its stake in shares of Aptorum Group by 88.0% in the 4th quarter. Susquehanna International Group LLP now owns 108,972 shares of the company’s stock valued at $163,000 after purchasing an additional 50,996 shares during the period. Renaissance Technologies LLC grew its stake in shares of Aptorum Group by 450.1% in the 4th quarter. Renaissance Technologies LLC now owns 81,958 shares of the company’s stock valued at $123,000 after purchasing an additional 67,058 shares during the period. Morgan Stanley lifted its holdings in Aptorum Group by 164.9% during the 3rd quarter. Morgan Stanley now owns 35,500 shares of the company’s stock worth $91,000 after buying an additional 22,100 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Aptorum Group during the 4th quarter worth $61,000. Hedge funds and other institutional investors own 4.64% of the company’s stock.

Aptorum Group Company Profile (Get Rating)

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.

Read More

Receive News & Ratings for Aptorum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptorum Group and related companies with MarketBeat.com's FREE daily email newsletter.